The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ANAPTYSBIO INC | COM | 032724106 | 35,537 | 1,590,733 | SH | SOLE | 1,590,733 | 0 | 0 | ||
| ARGENX SE | SPONSORED ADR | 04016X101 | 8,063 | 35,800 | SH | SOLE | 35,800 | 0 | 0 | ||
| ARROWHEAD PHARMACEUTICALS IN | COM | 04280A100 | 24,329 | 563,291 | SH | SOLE | 563,291 | 0 | 0 | ||
| BLUEPRINT MEDICINES CORP | COM | 09627Y109 | 24,572 | 315,029 | SH | SOLE | 315,029 | 0 | 0 | ||
| DICERNA PHARMACEUTICALS INC | COM | 253031108 | 36,949 | 1,454,686 | SH | SOLE | 1,454,686 | 0 | 0 | ||
| GALAPAGOS NV | SPON ADR | 36315X101 | 8,727 | 44,234 | SH | SOLE | 44,234 | 0 | 0 | ||
| MORPHOSYS AG | SPONSORED ADS | 617760202 | 3,037 | 95,898 | SH | SOLE | 95,898 | 0 | 0 | ||
| NGM BIOPHARMACEUTICALS INC | COM | 62921N105 | 21,619 | 1,095,184 | SH | SOLE | 1,095,184 | 0 | 0 | ||
| PIERIS PHARMACEUTICALS INC | COM | 720795103 | 17,284 | 5,575,530 | SH | SOLE | 5,575,530 | 0 | 0 | ||
| PROQR THRAPEUTICS N V | SHS EURO | N71542109 | 14,602 | 2,401,570 | SH | SOLE | 2,401,570 | 0 | 0 | ||
| REGENXBIO INC | COM | 75901B107 | 20,384 | 553,453 | SH | SOLE | 553,453 | 0 | 0 | ||
| SPDR SER TR S&P BIOTECH | UNIT | 78464A870 | 223,900 | 2,000,000 | SH | Put | SOLE | 0 | 0 | 2,000,000 | |
| SPERO THERAPEUTICS INC | COM | 84833T103 | 26,290 | 1,943,081 | SH | SOLE | 1,943,081 | 0 | 0 | ||
| UNIQURE NV | SHS | N90064101 | 30,624 | 679,620 | SH | SOLE | 679,620 | 0 | 0 | ||